Reuters logo
BRIEF-Newlink genetics announces FDA orphan-drug designation for Indoximod
October 30, 2017 / 1:37 PM / 23 days ago

BRIEF-Newlink genetics announces FDA orphan-drug designation for Indoximod

Oct 30 (Reuters) - Newlink Genetics Corp

* Newlink Genetics announces FDA orphan-drug designation for Indoximod

* ‍Indoximod was granted orphan-drug designation by U.S. FDA for treatment of patients with stage IIB-IV melanoma​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below